By Peter Orpen, Co-Owner & Formulator, Teelixir | Published March 2026 | Updated April 2026

How Lion's Mane Works: The NGF Pathway and What It Actually Does in the Brain

Most Lion's Mane articles start with the benefits. This one starts with the molecules.

That is a deliberate choice, because if you don't understand the mechanism, the benefits make no sense. You'll expect a stimulant effect — an immediate cognitive jolt — and be confused when nothing happens. Or you'll read a headline claiming Lion's Mane "boosts NGF" and have no idea what that means in practice or why it would matter to you.

The mechanism is this: Lion's Mane contains two compound families — hericenones and erinacines — that are, as far as the published literature shows, the only naturally-occurring, food-sourced compounds capable of stimulating nerve growth factor synthesis in neural tissue. Research has identified these compounds crossing into brain tissue (erinacines specifically), promoting NGF production, and in preclinical models driving measurable neuroplastic changes.

That mechanistic chain — molecule to NGF to neural repair — is what we call The NGF Pathway. Understanding it explains why Lion's Mane takes weeks to show effects, why the dose used and extraction method matter, and why the human evidence looks the way it does. For a full review of the benefits that evidence supports, see our broader benefits review with 77 studies.

The NGF Pathway: What Lion's Mane Activates and How

Nerve growth factor (NGF) is a protein produced by the body that supports the survival, growth, and maintenance of neurons — the cells that carry signals in your brain and nervous system. NGF is not a nutrient you consume. It is something your body makes. And its production declines with age.

Reduced NGF availability is associated with the neurodegeneration observed in Alzheimer's disease, Parkinson's disease, and age-related cognitive decline — though causality in humans is complex and not fully established. What is clear from the research is that when NGF synthesis is supported, neural repair and maintenance processes benefit.

The NGF Pathway describes the mechanism by which Lion's Mane upregulates the body's own NGF production. It does not deliver NGF exogenously — NGF cannot cross the blood-brain barrier when administered from outside. Instead, hericenones and erinacines act as NGF inducers: compounds that signal neural tissue to increase its own NGF synthesis.

This is why Lion's Mane is not a stimulant. It does not flood your brain with a signalling molecule. It supports an underlying maintenance process. That process takes weeks. Most studies on the mechanism were animal or in vitro; the human clinical evidence is consistent with the proposed pathway but has not directly measured NGF changes in brain tissue in a large-scale human trial.

"Hericenones and erinacines are the only naturally-occurring compounds identified in a food source that have been demonstrated to stimulate NGF synthesis in neural tissue — a distinction that makes Lion's Mane uniquely positioned in the evidence landscape for brain-targeted functional ingredients."

— Research summary based on published mechanistic literature (Mori et al., Kawagishi et al., 1994–2025)

Hericenones and Erinacines: The Two Compound Families

Hericium erinaceus — Lion's Mane — is botanically unusual in that its two primary neuroactive compound families come from different structural parts of the organism and behave differently in the body.

Hericenones are found in the fruiting body — the visible white cascading mushroom. These are diterpenoid aromatic compounds. In vitro studies have shown they stimulate NGF synthesis in astrocyte cell cultures. They are larger molecules. Studies suggest they work peripherally — stimulating NGF production in the enteric nervous system and peripheral nerve tissue, which then signals centrally.

Erinacines are found in the mycelium — the root-like underground network. These are cyathane-type diterpenoids. Erinacine A in particular has been studied for blood-brain barrier penetration. In animal models, oral erinacine A supplementation increased NGF levels in the hippocampus and locus coeruleus — two brain regions central to memory and attention. They are smaller and more lipophilic than hericenones, which supports their blood-brain barrier crossing capacity.

This structural split is why product choice matters. A fruiting-body-only product captures hericenones but misses erinacines. A mycelium-only product risks the opposite — and may also introduce starch dilution if the mycelium is grown on grain substrate and not separated before processing. For a detailed comparison, see our Fruiting Body vs Mycelium guide.

Why Dual-Extraction Matters for Brain-Targeted Compounds

Hericenones and erinacines are diterpenoid compounds. Diterpenoids are not water-soluble. Hot-water extraction — the most common method used in commodity mushroom products — captures polysaccharides (beta-glucans, immunomodulatory compounds) effectively, but fails to extract diterpenoids in meaningful concentrations.

This is the extraction gap that most Lion's Mane articles never address. If you are purchasing a water-extracted Lion's Mane product and expecting the compound families studied in the NGF mechanism research, you are working from an incomplete profile. The beta-glucans are present. The hericenones and erinacines are largely absent.

Ethanol extraction specifically targets diterpenoid fractions. A genuine dual-extraction process uses both stages: hot water to capture polysaccharides, then ethanol to capture diterpenoids. The resulting extract contains the full active compound profile. This is what we call The Dual-Extract Advantage — and it is not a marketing claim. It is a chemistry requirement for capturing both compound families shown to be relevant to the NGF mechanism.

When assessing any Lion's Mane product, you can aim for products that specify both extraction stages — not just "extracted" as a general claim. For a practical comparison of product forms, see our article on Lion's Mane powder vs extract vs capsules.

What the Mechanism Evidence Shows

The mechanistic evidence for The NGF Pathway is primarily preclinical — animal models and in vitro cell studies. That is the honest statement. Here is what the research has actually demonstrated at each level.

Preclinical Mechanistic Evidence

In rat astrocyte models, hericenones stimulated NGF mRNA expression and NGF protein secretion in a dose-dependent manner. Erinacine A in rats increased NGF levels in the hippocampus and locus coeruleus — two regions central to memory and attention — following oral supplementation. Erinacine E and erinacine S showed similar NGF-promoting activity in rodent models. The animal evidence for the NGF mechanism is consistent and replicated across multiple research groups over three decades.

Human RCT Outcomes Consistent with the Mechanism

The human evidence does not directly measure NGF levels in brain tissue — technically impractical in a non-invasive trial. What it measures are the downstream cognitive outcomes that would be expected if the NGF mechanism were operating. Outcomes observed in four human RCTs are consistent with The NGF Pathway at doses used in studies.

The gradual onset pattern and reversal on cessation (PMID: 18844328) is particularly significant mechanistically. Stimulants show immediate effects that disappear when the dose wears off. NGF-dependent neuroplasticity would be expected to build gradually and then decay once the stimulus is removed — exactly the pattern observed.

Why Mechanism Doesn't Always Translate to Outcomes

A compelling preclinical mechanism does not guarantee a clinically meaningful human outcome. This is not a caveat — it is the honest structural limitation of The NGF Pathway research as it stands in 2026, and understanding it matters for setting appropriate expectations.

• The 2023 pilot RCT (PMID: 38004235) found no significant effect on processing speed in healthy young adults — even with improved composite cognition scores. Not every cognitive domain responds to the mechanism equally.
• The animal models that confirmed erinacine A crosses the blood-brain barrier have yet to be confirmed with equivalent methodology in humans. The assumption of equivalent penetration in humans is reasonable but not yet directly measured.
• Human RCTs did not demonstrate clinically meaningful benefit for severe cognitive decline or advanced dementia. The evidence base is restricted to mild cognitive impairment and healthy adults.
• Most mechanistic studies were conducted in rodent models. Rodent NGF biology and human NGF biology are similar but not identical. Dose-scaling and bioavailability comparisons across species introduce uncertainty.
• No Cochrane systematic review of Lion's Mane exists for cognitive outcomes. Without population-level meta-analysis, we cannot draw conclusions with the same confidence as better-reviewed interventions.
• A 2024 human trial (PMID: 38140277) observed effects on cognitive biomarkers — intermediate biological signals — but the translation of biomarker changes to real-world cognitive performance has yet to be confirmed in humans in a long-term outcome trial.

These are not reasons to dismiss the evidence. They are reasons to hold it accurately. The NGF mechanism is well-characterised preclinically. The human outcomes are consistent with it. The gap between "mechanism demonstrated" and "clinically meaningful outcome proven" is real, and any honest account of this ingredient must acknowledge it.

What This Means in Practice

Understanding the mechanism changes how you should approach Lion's Mane practically. Here is what the combined mechanistic and clinical picture actually implies for use.

Who the Mechanism Evidence Points Toward

Adults over 50 with mild cognitive concerns have the strongest signal in the human evidence base. This makes mechanistic sense: NGF levels naturally decline with age, and a population starting from a reduced NGF baseline would be more sensitive to NGF upregulation than a healthy young adult with normal levels. If you are in this category, consider a consistent daily protocol of at least 8-12 weeks before assessing results. You can start with 1-2g daily of dual extract at doses used in studies.

For healthy younger adults, the 2023 RCT data suggests you may want to focus on mood and stress outcomes rather than processing speed. Begin with 1g daily of dual extract and try increasing to 2-3g over 4-6 weeks if well tolerated. Pair alongside lifestyle factors that also support NGF synthesis — quality sleep, exercise, and reduced inflammatory load.

Stacking with the Mechanism in Mind

Lion's Mane combines well alongside adaptogens that address different mechanisms. Pairing it alongside Reishi (for cortisol and immune modulation) or Cordyceps (for cellular energy via ATP pathways) addresses complementary biological pathways — there is no mechanism-level reason to expect negative interactions. For more on nervous system stacking, see our Lion's Mane for anxiety article on combining adaptogens.

When the Mechanism Won't Help

Lion's Mane is not appropriate as a short-term solution. Taking it two days before an important event expecting a stimulant effect is not consistent with the NGF mechanism — which requires weeks of upregulation, not single-dose activation. It is unlikely to help with acute cognitive demands without an established baseline of consistent use. It is not recommended as a replacement for prescribed treatments for diagnosed cognitive conditions — if you are considering it alongside pharmaceutical medications, consult your healthcare professional first.

Is the NGF Mechanism Relevant to Your Situation?

Dose-Mechanism Relationship

At doses used in studies, 3g per day of dried mushroom powder produced the most significant and sustained effects in the primary RCT (PMID: 18844328), measuring over 16 weeks in n=30 participants with mild cognitive impairment. No dose-comparison trial has been published in humans. We cannot state that 3g is definitively optimal — only that 3g was the dose at which significant effects were observed.

For extract products, the equivalent dose depends on the extraction ratio. A 10:1 dual extract means 1g of extract is theoretically equivalent to 10g of dried powder — though bioavailability comparisons across product forms have not been established in human trials. Begin with a consistent daily dose rather than sporadic higher doses. The mechanism requires sustained NGF upregulation over weeks, not single-serving loading. Start with 1g daily and increase to 2-3g over 4-6 weeks if well tolerated.

For complete dosage protocols and timing guidance, see our Lion's Mane Dosage Guide.

From Our Formulations: What We Test For

The mechanistic research described above is why we formulate the way we do. This is not abstract brand philosophy — it is a direct response to the chemistry.

Dual Extraction Process

Our Lion's Mane undergoes a two-stage extraction process: hot-water extraction to capture polysaccharides (primarily beta-glucans), followed by ethanol extraction to capture the diterpenoid fractions — hericenones and erinacines. Without both stages, the product does not reflect the full compound profile studied in the NGF mechanism research. We specify both extraction stages in product documentation because a general "extracted" claim does not tell you which stages were used.

Di Tao Origin and COA Verification

Di tao — the traditional Chinese principle of authentic geographic origin — applies here because Lion's Mane grown in its native habitat under natural conditions produces different phytochemical concentrations than mushrooms cultivated in controlled environments on grain substrates. Our Lion's Mane is sourced from di tao origin regions in China, with ACO (Australian Certified Organic) certification. Every batch is third-party tested for heavy metals, microbiological contaminants, and identity verification.

The primary quantifiable marker we verify batch-by-batch is beta-glucan content — the standard polysaccharide marker for mushroom extract quality. Our COA C24051507 confirmed 31.7% beta-glucans on a tested batch, sourced through our supplier Xi'an Lifewe Biotech (Yes Herbs). We also verify the absence of starch-based fillers — a common adulterant in commodity mushroom products where mycelium-on-grain substrate introduces significant grain starch into the extract, diluting active compound concentration per gram.

What We Observe in Practice

From our formulation experience, the most consistent quality gap in commodity Lion's Mane products is not the extraction method claim — it is the source material. Mycelium-on-grain products, cheaper to produce, carry a significant starch burden that reduces the proportion of active compounds per gram of product. A 10:1 extract ratio means very little if the starting material is 40% grain starch. We require confirmed fruiting body material and verify this through supplier COA documentation on every batch. For customers who prefer a capsule format, we offer an Australian-grown Lion's Mane capsule alternative produced under ACO organic certification.

Safety Profile

Lion's Mane is generally well tolerated at doses used in studies. The 2025 systematic review (PMID: 40959699) noted a favourable safety profile across human trials reviewed. No serious adverse events were reported in the published RCTs.

Some individuals report mild gastrointestinal effects when starting supplementation — typically resolving within the first week. If you experience persistent discomfort, reduce the dose and increase gradually.

Lion's Mane is not recommended during pregnancy or breastfeeding, as no safety data exists in these populations. It is not suitable as a replacement for prescribed medications without medical guidance. If you are taking anticoagulants, diabetes medications, or any drug metabolised by the liver, consult your healthcare professional before starting Lion's Mane. The human drug interaction profile has not been systematically studied.

For a full review of the side effect data, including rare cases of contact dermatitis reported in occupational exposure studies, see our companion article: Lion's Mane Side Effects.

Frequently Asked Questions

Disclaimer: This article is for educational purposes only and is not intended to diagnose, treat, cure or prevent any disease. The information presented reflects the current published scientific literature and is not a substitute for professional medical advice. Consult your healthcare professional before starting any supplement regimen, particularly if you are pregnant, breastfeeding, taking medications, or managing a health condition.

Continue Your Research

• Lion's Mane Benefits: What 77 Studies Actually Show — broader benefits review with the full evidence base
• What the Human Trials Actually Show — detailed walkthrough of the RCTs
• Lion's Mane for Dementia and Alzheimer's — Alzheimer's and dementia evidence in depth
• Fruiting Body vs Mycelium: Does the Source Material Matter? — compound source comparison
• Lion's Mane Dosage Guide — dose protocols from the clinical evidence
• Powder vs Extract vs Capsules: Form and Mechanism — form comparison for the mechanism-aware buyer

← Back to Lion's Mane Research Hub